Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement.

"Author disclosures S. Reyes has received speaking honoraria or scientific advisory fees from Merck, Novartis and Biogen; A.L. Cunningham's institution has received speaking honoraria or scientific advisory fees from Merck; T. Kalincik served on scientific advisory boards for Roche, Sanofi Genzyme, Novartis, Merck and Biogen, steering committee for Brain Atrophy Initiative by Sanofi Genzyme, received conference travel support and/or speaker honoraria from WebMD Global, Novartis, Biogen, Sanofi Genzyme, Teva, BioCSL and Merck and received research or educational event support from Biogen, Novartis, Genzyme, Roche, Celgene and Merck; E. Kubala Havrdová has received honoraria/research support from Biogen, Merck Serono, Novartis, Roche, and Teva; has served as a member of advisory boards for Actelion, Biogen, Celgene, Merck Serono, Novartis, and Sanofi Genzyme; has been supported by the Czech Ministry of Education research project PROGRES Q27/LF1; N. Isobe has received speaking honoraria from Novartis Pharma, Biogen Japan, Mitsubishi Tanabe Pharma, Alexion, and Takeda Pharmaceutical Company; J. Pakpoor has received speaking honoraria/scientific advisory board fees from EMD Serono; L. Airas has received institutional research grants from Merck Serono and Sanofi Genzyme. She has obtained compensation for advisory board work from Roche, Biogen Idec, Sanofi Genzyme and Merck Serono; R.F. Bunyan has received speaker honoraria and travel support from Merck, Novartis, and Roche; A. van der Walt served on advisory boards and receives unrestricted research grants from Novartis, Biogen, Merck and Roche She has received speaker's honoraria and travel support from Novartis, Roche, and Merck. She receives grant support from the National Health and Medical Research Council of Australia and MS Research Australia; J. Oh has received grants from MS Society of Canada, Love-Barford Endowment of St. Michael's Hospital Foundation, National MS Society, Brain Canada, Biogen Idec, Roche, and EMD Serono; and personal fees for consulting or speaking from Biogen Idec, EMD Serono, Roche, Sanofi Genzyme, Novartis, and Celgene; J. Mathews has received conference sponsorship and hospitality payments from Biogen, Celegene, Merck, Novartis, Roche, and Sanofi; F.J. Mateen has received consulting fees and research support from Biogen; G. Giovannoni has received consultancy, presentation fees or grants from AbbVie Biotherapeutics, Bayer Healthcare, Biogen, Canbex, Celgene, Ironwood, Japan Tobacco, Novartis, Roche, Sanofi Genzyme, Synthon, Takeda, Teva and Vertex."

"Funding Funding for medical writing and editorial support from Oxford PharmaGenesis was provided by Oxford Health Policy Forum CIC, a not-for-profit community interest company."